The French biotechnology company, Inatherys, specializes in discovering and developing drugs using monoclonal antibodies to treat severe inflammatory diseases and cancer. Their proprietary antibodies, INA01 and INA02, target specific receptors to prevent cellular activation and proliferation of cancer cells and inflammation. With a focus on biotechnology solutions, Inatherys is based in Evry, France and is dedicated to developing monoclonal antibodies for the treatment of cancers and inflammatory diseases.